Altimmune Inc
ALT
Company Profile
Business description
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Contact
910 Clopper Road
Suite 201S
GaithersburgMD20878
USAT: +1 240 654-1450
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
59
Stocks News & Analysis
stocks
Have the 3 biggest losers of the ASX 200 fallen too far?
Finding value in some of the ASX’s worst recent performers.
stocks
Rethinking the way we invest in Aussie tech
Investing in Tech companies has many caveats from traditional investing. Let’s dive into how you can gauge the true profitability of a tech company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,866.40 | 56.60 | -0.63% |
| CAC 40 | 8,083.07 | 39.64 | -0.49% |
| DAX 40 | 23,552.71 | 284.08 | -1.19% |
| Dow JONES (US) | 47,463.23 | 253.19 | -0.53% |
| FTSE 100 | 9,718.92 | 1.59 | -0.02% |
| HKSE | 26,033.26 | 174.37 | 0.67% |
| NASDAQ | 23,197.86 | 167.82 | -0.72% |
| Nikkei 225 | 49,303.28 | 950.63 | -1.89% |
| NZX 50 Index | 13,448.49 | 40.66 | -0.30% |
| S&P 500 | 6,812.16 | 36.93 | -0.54% |
| S&P/ASX 200 | 8,565.20 | 48.90 | -0.57% |
| SSE Composite Index | 3,914.01 | 25.41 | 0.65% |